natgillin/translations-raw huggingface dataset:
carbamazepine, phenobarbital and phenytoin (antiepileptics used to prevent seizures)
karbamazepin, fenobarbital i fenitoin (antiepileptici koji se koriste za sprječavanje napadaja)
Carbamazepine, phenobarbital and phenytoin (medicines used to treat epilepsy and prevent seizures).
karbamazepin, fenobarbital i fenitoin (lijekovi koji se primjenjuju za liječenje epilepsije i sprječavanje napadaja).
carbamazepine, phenobarbital and phenytoin (medicines used to treat epilepsy and prevent seizures);
karbamazepin, fenobarbital i fenitoin (lijekovi koji se primjenjuju za liječenje epilepsije i sprječavanje napadaja);
Carbamazepine, phenobarbital and phenytoin (strong CYP3A4/5 inducers)
Karbamazepin, fenobarbital i fenitoin (snaţni induktori CYP3A4/5)
Carbamazepine, phenobarbital or phenytoin.
ako uzimate lijekove koji sadrže neku od sljedećih djelatnih tvari: karbamazepin, fenobarbital ili fenitoin.
Carbamazepine, phenobarbital or phenytoin.
Karbamazepin, fenobarbital ili fenitoin.
Carbamazepine, phenobarbital phenytoin
Karbamazepin, fenobarbital,
carbamazepine, phenobarbital, phenytoin (medicines for epilepsy);
karbamazepin, fenobarbital, fenitoin (lijekovi za liječenje epilepsije);
carbamazepine, phenobarbital, phenytoin (medicines to prevent seizures)
karbamazepin, fenobarbital, fenitoin (lijekovi za sprječavanje napadaja)
carbamazepine, phenobarbital, phenytoin (used to prevent seizures)
karbamazepin, fenobarbital, fenitoin (primjenjuju se za sprječavanje napadaja)
carbamazepine, phenobarbital, phenytoin (used to treat epilepsy)
karbamazepin, fenobarbital, fenitoin (koriste se za liječenje epilepsije)
carbamazepine, phenobarbital, phenytoin – used to treat epilepsy; rifampicin – used to treat tuberculosis;
karbamazepin, fenobarbital, fenitoin – koriste se za liječenje epilepsije;
carbamazepine, phenobarbital, phenytoin, used to prevent seizures
karbamazepin, fenobarbital, fenitoin, primjenjuju se za sprječavanje napadaja
carbamazepine, phenobarbital, phenytoin, used to treat epilepsy and prevent seizures
karbamazepin, fenobarbital, fenitoin, koji se primjenjuju za liječenje epilepsije i sprečavanje napadaja
carbamazepine, phenobarbital, phenytoin, used to treat epilepsy and prevent seizures
karbamazepin, fenobarbital, fenitoin, koji se primjenjuju za liječenje epilepsije i sprječavanje napadaja
carbamazepine, phenytoin
karbamazepin, fenitoin
carbamazepine, phenytoin (anti-seizure medicines)
karbamazepin, fenitoin (lijekovi protiv napadaja),
carbamazepine, phenytoin (medicines to treat epilepsy or other illness). warfarin, dipyridamole, phenprocoumon, low-dose acetylsalicylic acid (blood thinning medicines).
karbamazepin, fenitoin (lijekovi za liječenje epilepsije i drugih bolesti). varfarin, dipiridamol, fenprokumon, niske doze acetilsalicilne kiseline (lijekovi za razrjeđivanje krvi).
Carbamazepine, phenytoin (used to treat seizures)
Karbamazepin, fenitoin (koji se koriste za liječenje napadaja)
carbamazepine, phenytoin – used for epilepsy,
karbamazepin, fenitoin – koriste se kod epilepsije,
carbamazepine, phenytoin, or phenobarbital (medicines used to control seizures) efavirenz or ritonavir (a medicine used to treat HIV infection)
karbamazepin, fenitoin ili fenobarbital (lijekovi koji se uzimaju za kontrolu napadaja) efavirenz ili ritonavir (lijek koji se uzima za liječenje HIV infekcije)
carbamazepine, phenytoin, or phenobarbital (medicines used to control seizures) efavirenz or ritonavir (medicines used to treat HIV infection)
karbamazepin, fenitoin ili fenobarbital (lijekovi koji se uzimaju za kontrolu napadaja) efavirenz ili ritonavir (lijekovi koji se koriste za liječenje HIV infekcije)
carbamazepine, phenytoin, phenobarbital
karbamazepin, fenitoin, fenobarbital
Carbamazepine, phenytoin, phenobarbital - used to treat seizures.
Karbamazepin, fenitoin, fenobarbital - primjenjuju se za liječenje napadaja.
carbamazepine, phenytoin, phenobarbital, lamotrigine (antiepileptics)
karbamazepin, fenitoin, fenobarbital, lamotrigin (antiepileptici)
carbamazepine, S-mephenytoin, phenytoin, medicines used to prevent seizures
karbamazepin, S-mefenitoin, fenitoin, lijekovi koji se primjenjuju za sprječavanje napadaja
carbamazepine, used for epilepsy,
karbamazepin za liječenje epilepsije,
Carbamazepine-10,11-epoxide: AUC: ↓ 35%
Karbamazepin-10,11-epoksid: AUC: ↓ 35
Carbamazepine/Dolutegravir
karbamazepin/dolutegravir
Carbamazepine/Efavirenz (400 mg once daily/600 mg once daily)
(50 mg jedanput na dan/600 mg
Carbamazepine/efavirenz (400 mg once daily/600 mg once daily)
Karbamazepin/efavirenz
Carbamazepine/Efavirenz (400 mg once daily/600 mg once daily)
karbamazepin/efavirenz (400 mg jedanput na dan/600 mg jedanput na dan)
Carbamazepine/Efavirenz (400 mg q.d./600 mg q.d.)
karbamazepin/efavirenz (400 mg q.d./600 mg q.d.)
Carbamazepine/Tenofovir disoproxil fumarate
karbamazepin/tenofovirdizoproksil fumarat
carbamazepine: a medicine to treat epilepsy, euphoric/depressive stages and certain pain conditions.
karbamazepin: lijek za liječenje epilepsije, euforičnih/depresivnih stanja i određenih bolnih stanja.
Carbamazepine: AUC: ↑ 43%
Karbamazepin: AUC: ↑ 43
carbamazepine;
karbamazepin;
Carbboard box with 1 bottle of 100 ml.
Kartonska kutija s 1 bočicom od 100 ml.
Carbomer .........................................................................................................................................
Karbomer .........................................................................................................................................
Carbomer ...........................................................................................................................................4 mg.
Karbomer............................................................................................................................................4 mg
Carbomer 1 mg
Karbomer 1 mg
Carbomer 971 P NF 2.0 mg
Karbomer 971 P NF 2,0 mg
Carbomer 971 P NF Thiomersal
Karbomer 971 P NF Tiomersal
Carbomer Methylparahydroxybenzoate (E218) Phenoxyethanol
karbomer metilparahidroksibenzoat (E218) fenoksietanol
Carbomer Sodium chloride
Karbomer Natrij klorid
Carbomer Sodium chloride
Karbomer Natrijev klorid
Carbomer.........................................................................................................................................
Karbomer...........................................................................................................................................
Carbomer...........................................................................................................................................4 mg.
Karbomer............................................................................................................................................4 mg
carbonate
(2400 mg u jednokratnoj
Carbonic anhydrase (CA) is an enzyme found in many tissues of the body, including the eye.
Karboanhidraza (CA) je enzim nađen u mnogim tkivima u tijelu, uključujući i oči.
Carbonic anhydrase catalyses the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid.
Karboanhidraza katalizira reverzibilnu reakciju koja obuhvaća i hidraciju ugljičnog dioksida i dehidraciju ugljične kiseline.
Carboxy- dabrafenib is excreted in bile and urine.
Karboksi- dabrafenib se izlučuje u žuč i urin.
Carboxy-dabrafenib can be decarboxylated via a non-enzymatic process to form desmethyl-dabrafenib.
Karboksi-dabrafenib se može dekarboksilirati kroz neenzimatski proces pri čemu se stvara dezmetil-dabrafenib.
Carcass
Tijelo
Carcinogenesis, mutagenesis, reproductive toxicity
Karcinogeneza, mutageneza, reproduktivna toksičnost
Carcinogenesis: No carcinogenicity data for interferon beta-1a are available in animals or humans.
Kancerogeneza: nema dostupnih podataka o kancerogenom djelovanju interferona beta-1a na ljude i životinje.
Carcinogenic potential in rodents was only investigated with orally administered aprepitant.
Rizik od nastanka karcinoma u glodavaca ispitan je samo nakon peroralne primjene aprepitanta.
Carcinogenicity / mutagenicity
Kancerogenost / mutagenost
Carcinogenicity and genotoxicity studies have not been conducted with Nutropin Aq.
Nije provedeno ispitivanje kancerogenosti i genotoksičnosti s lijekom NutropinAq.
Carcinogenicity studies conducted in mouse and rat showed increased incidences of lymphomas (male and female mouse), hepatocellular adenoma and carcinoma (male mouse) and granulocytic leukaemia (female mouse).
Ispitivanja karcinogenosti koje su provedene u miševa i štakora pokazala su porast incidencije limfoma (mužjaci i ženke miševa), hepatocelularnog adenoma i karcinoma (mužjaci miševa) te granulocitne leukemije (ženke miševa).
Carcinogenicity studies conducted in mouse and rat showed increased incidences of lymphomas (male and female mouse), hepatocellular adenoma and carcinoma (male mouse) and granulocytic leukaemia (female mouse).
Ispitivanja karcinogenosti provedena u miševa i štakora pokazala su porast incidencije limfoma (mužjaci i ženke miševa), hepatocelularnog adenoma i karcinoma (mužjaci miševa) te granulocitne leukemije (ženke miševa).
Carcinogenicity studies did not indicate any oncogenic potential in rats, whereas increased incidences of hepatocellular tumors in male mice are considered to result of a non-genotoxic, mode of action linked to a phenobarbitone- like liver enzyme induction, which is a known rodent specific phenomenon.
Ispitivanja kancerogenosti nisu ukazala na onkogeni potencijal u štakora, a povećane incidencije hepatocelularnih tumora u mužjaka miševa smatrale su se posljedicom negenotoksičnog mehanizma djelovanja povezanog s indukcijom jetrenih enzima nalik onoj koju uzrokuje fenobarbiton, za koju se zna da je fenomen specifičan za glodavce.
Carcinogenicity studies have not been conducted with cobimetinib.
Nisu provedena ispitivanja kancerogenosti kobimetiniba.
Carcinogenicity studies have not been conducted with GIOTRIF.
Nisu provođena ispitivanja kancerogenosti s GIOTRIFOM.
Carcinogenicity studies have not been conducted with ibrutinib.
Nisu provedena ispitivanja kancerogenosti s ibrutinibom.
Carcinogenicity studies have not been conducted with olaparib.
Nisu provedena ispitivanja kancerogenosti olapariba.
Carcinogenicity studies have not been performed with ALA.
Ispitivanja kancerogenosti nisu provedena s aminolevulinskom kiselinom.
Carcinogenicity studies have not been performed with axitinib.
Nisu provedena ispitivanja kancerogenosti aksitiniba.
Carcinogenicity studies have not been performed with sonidegib, but sonidegib was not genotoxic in studies conducted in vitro and in vivo.
Ispitivanja kancerogenosti nisu provođena sa sonidegibom, ali sonidegib nije bio genotoksičan u ispitivanjima provedenim in vitro i in vivo.
Carcinogenicity studies of 2 years’ duration did not reveal a carcinogenic potential at exposures 18- fold and 116-fold the human exposure in rats and mice, respectively.
Dvogodišnja ispitivanja kancerogenosti u miševa i štakora, nisu otkrila kancerogeni potencijal pri izloženosti 18 puta većoj odnosno 116 puta većoj od izloženosti kod ljudi.
Carcinogenicity studies of dimethyl fumarate were conducted for up to 2 years in mice and rats.
Ispitivanja karcinogenosti dimetilfumarata provedena su u razdoblju do 2 godine u miševa i štakora.
Carcinogenicity studies were not performed with ustekinumab due to the lack of appropriate models for an antibody with no cross-reactivity to rodent IL-12/23 p40.
Ispitivanja kancerogenosti nisu provedena s ustekinumabom zbog nedostatka odgovarajućih modela za protutijela s ne križnom reaktivnošću na IL-12/23 p40 glodavaca.
Carcinogenicity studies with idelalisib have not been conducted.
Ispitivanja kancerogenosti idelalisiba nisu provedena.
Carcinogenicity studies with velpatasvir are ongoing.
Ispitivanja kancerogenosti s velpatasvirom su u tijeku.
Carcinogenicity studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel due to the development of neutralising antibodies in rodents.
Ispitivanja karcinogenosti, kao i uobičajena procjena utjecaja na plodnost i postnatalne toksičnosti, nisu provedena s Enbrelom zbog pojave neutralizirajućih protutijela u glodavaca.
Carcinogenicity studies, and standard assessments of fertility and postnatal toxicity, were not performed with etanercept due to the development of neutralising antibodies in rodents.
Ispitivanja karcinogenosti, kao i uobičajena procjena utjecaja na plodnost i postnatalne toksičnosti, nisu provedena s etanerceptom zbog pojave neutralizirajućih protutijela u glodavaca.
Carcinogenicity, mutagenicity, and impairment of fertility studies with CE/bazedoxifene have not been conducted.
Ispitivanja kancerogenosti, mutagenosti i oštećenja plodnosti s KE/bazedoksifenom nisu provedena.
Carcinoid tumour
Karcinoid
Carcinoma of the endometrium or other known or suspected oestrogen-dependent neoplasia
Karcinom endometrija ili druge potvrđene novotvorine ovisne o estrogenu ili sumnja na njih.
carcinoma of the skin)1)
karcinom kože)1)
carcinoma)
tanica),
carcinoma),
tanica),
card
blister
Card of 1 pipette
Kartica s 1 pipetom
Cardalis 10 mg/80 mg chewable tablets for dogs Benazepril hydrochloride 10 mg, spironolactone 80 mg
Cardalis 10 mg/80 mg tablete za žvakanje za pse benazepril HCl 10 mg, spironolakton 80 mg
Cardalis 2.5 mg/20 mg chewable tablets
Cardalis 2,5 mg/20 mg tablete za žvakanje
Cardalis 2.5 mg/20 mg chewable tablets for dogs Benazepril hydrochloride 2.5 mg, spironolactone 20 mg
Cardalis 2,5 mg/20 mg tablete za žvakanje za pse benazepril HCl 2,5 mg, spironolakton 20 mg
Cardalis 2.5 mg/20 mg chewable tablets for dogs Cardalis 5 mg/40 mg chewable tablets for dogs Cardalis 10 mg/80 mg chewable tablets for dogs
Cardalis 2,5 mg/20 mg tablete za žvakanje za pse Cardalis 5 mg/40 mg tablete za žvakanje za pse Cardalis 10 mg/80 mg tablete za žvakanje za pse
Cardalis 5 mg/40 mg chewable tablets for dogs Benazepril hydrochloride 5 mg, spironolactone 40 mg
Cardalis 5 mg/40 mg tablete za žvakanje za pse benazepril HCl 5 mg, spironolakton 40 mg
Cardalis chewable tablets should be administered to the dog once a day using a dosage of 0.25 mg/kg bodyweight (bw) benazepril hydrochloride (HCl) and 2 mg/kg bodyweight spironolactone, according to the following dosage table.
Cardalis tablete za žvakanje treba davati psu jednom dnevno primjenom doze od 0,25 mg/kg tjelesne težine benazepril hidroklorida (HCl) i 2 mg/kg tjelesne težine (bw) spironolaktona u skladu sa sljedećom tablicom doziranja.
Cardalis chewable tablets should be administered to the dog once a day using a dosage of 0.25 mg/kg bodyweight benazepril hydrochloride (HCl) and 2 mg/kg bodyweight (bw) spironolactone, according to the following dosage table.
Cardalis tablete za žvakanje treba davati psu jednom dnevno primjenom doze od 0,25 mg/kg tjelesne težine benazepril hidroklorida (HCl) i 2 mg/kg tjelesne težine (bw) spironolaktona u skladu sa sljedećom tablicom doziranja.
Cardboard box
Kartonske kutije
CARDBOARD BOX
Kutija
Cardboard box (10, 20, 50, 100, 200, 250 or 500 ml)
Kartonska kutija (10, 20, 50, 100, 200, 250 ili 500 ml )
Cardboard box (20 ml / 50 ml / 100 ml / 250 ml)
Kartonska kutija (20 ml / 50 ml / 100 ml / 250 ml)
Cardboard box (50 ml / 100 ml / 250 ml)
Kartonska kutija (50 ml / 100 ml / 250 ml)
Cardboard box (500 ml)
Kartonska kutija (500 ml)
Cardboard box (52 ml, 100 ml and 252 ml)
Kartonska kutija (52 ml,100 ml i 252 ml)
Cardboard box (with PET bottle of 50 ml or 100 ml)
Kartonska kutija (s jednom PET bočicom od 50 ili 100 ml)
Cardboard box / Solution for injection
Kartonska kutija/Otopina za injekciju
Cardboard box / Tablets
Kartonska kutija/Tableta
Cardboard box and HDPE bottle,
Kartonska kutija i HDPE boca
Cardboard box containing 1 colourless glass injection vial of 20 ml, 50 ml or 100 ml.
Kartonska kutija sadrži 1 bezbojnu staklenu bočicu od 20 ml, 50 ml ili 100 ml zatvorena gumenim čepom i bromobutil zatvorena aluminijskim čepom.
Cardboard box containing 1 high-density polyethylene bottle of 100 or 250 tablets with a child resistant closure.
Kartonska kutija koja sadrži 1 bocu od polietilena visoke gustoće sa 100 ili 250 tableta, sa sigurnosnim zatvaračem za djecu.
Cardboard box containing 1 vial of 50, 100, 250 or 500 ml.
Kutija sadrži jednu bočicu od 50, 100, 250 ili 500 ml.
Cardboard box containing 1, 2, 4 or 10 Alu/Alu blisters.
Kartonska kutija koja sadrži 1, 2, 4 ili 10 Al/Al blistera.
Cardboard box containing 1, 2, 5 or 10 Alu/Alu blisters.
Kartonska kutija koja sadrži 1, 2, 5 ili 10 Al/Al blistera.
Cardboard box containing 1, 3, 4 or 15 unit dose applicator(s) of 0.3 ml each.
Kartonska kutija s 1, 3, 4, ili 15 aplikatora, s jediničnom dozom od 0,3 ml svaki..
Cardboard box containing 2, 12, 20 or 40 tubes (each containing 2.05 g).
Kartonska kutija koja sadrži: 2, 12, 20 ili 40 tuba (svaka sadrži 2,05 g).
Cardboard box containing 20 pentalaminate sachets (inner coating LDPE) of 3 g (containing 100 mg prednisolone), or 10 sachets of 9 g (containing 300 mg prednisolone) or 18 g (containing 600 mg prednisolone) of oral powder.
Kartonska kutija sadrži 20 pentalaminatna vrećica (unutarnji sloj od LDPE) od 3 g (sadrži 100 mg prednizolona), ili 10 vrećica od 9 g (sadrži 300 mg prednizolona) ili 18 g (sadrži 600 mg prednizolona) peroralnog praška.
Cardboard box containing 3 or 18 blisters of 10 tablets.
Kartonska kutija sadržava 3 ili 18 blistera sa po 10 tableta.
Cardboard box containing 56 or 168 hard capsules in PVC/Aclar – Aluminium foil blisters
Kartonska kutija s 56 ili 168 tvrdih kapsula u blisterima od PVC/Aclar-aluminijske folije,
Cardboard box containing 56 or 168 hard capsules in PVC/Aclar – Aluminium foil blisters
Kartonska kutija s 56 ili 168 tvrdih kapsula u blisterima od PVC/Aclar-aluminijske folije.
Cardboard box containing 56x1, 84x1, 112x1, 140x1, 168x1 hard capsules in PVC/Aclar – Aluminium foil perforated unit dose blisters
Kartonska kutija s 56 × 1, 84 × 1, 112 × 1, 140 × 1 ili 168 × 1 tvrdih kapsula u perforiranim blisterima djeljivim na jedinične doze od PVC/Aclar-aluminijske folije,
Cardboard box containing 56x1, 84x1, 112x1, 140x1, 168x1 hard capsules in PVC/Aclar – Aluminium foil perforated unit dose blisters
Kartonska kutija s 56x1, 84x1 112x1, 140x1ili 168x1 tvrdih kapsula u perforiranim blisterima djeljivim na jedinične doze od PVC/Aclar- aluminijske folije,
Cardboard box containing blister, each containing 3 or 6 chewable tablets.
Kartonska kutija s prozirnim blisterom koji sadrži 3 ili 6 tableta za žvakanje.
Cardboard box containing one 10 ml vial.
Kartonska kutija sadržava jednu bočicu od 10 ml.
Cardboard box containing one 124 ml HDPE bottle filled with 100 ml closed with a LDPE plug-in adapter and a tamper-proof child resistant closure and a measuring syringe.
Kartonska kutija koja sadrži jednu HDPE bočicu od 124 ml napunjenu s 100 ml i zatvorenu LDPE nastavkom s otvorom za štrcaljku i zatvaračem sigurnim za djecu te mjernom štrcaljkom.
Cardboard box containing one 45 ml HDPE bottle filled with 30 ml closed with a LDPE plug-in adapter and a tamper-proof child resistant closure and a measuring syringe.
Kartonska kutija koja sadrži jednu HDPE bočicu od 45 ml napunjenu s 30 ml i zatvorenu LDPE nastavkom s otvorom za štrcaljku i zatvaračem sigurnim za djecu te mjernom štrcaljkom.
Cardboard box containing one colourless glass injection vial of 10 ml or 20 ml, closed with a rubber stopper and sealed with an aluminium cap.
Kartonska kutija sadrži jednu bezbojnu staklenu injekcijsku bočicu od 10 ml ili 20 ml, zatvorenu gumenim čepom i osiguranu aluminijskom kapicom.
Cardboard box containing one colourless glass vial of 20 ml, 50 ml, 100 ml or 250 ml.
Kartonska kutija s 1 bezbojnom staklenom bočicom od 20 ml, 50 ml, 100 ml ili 250 ml.
Cardboard box containing one glass vial (Hydrolytic Type I) of 20 ml or 50 ml.
Kartonska kutija sadrži jednu staklenu bočicu od 20 ml ili 50 ml.
Cardboard box containing one HDPE (white) jar with LDPE tear band lid containing 180 gram or 504 gram of oral powder and one polystyrene (colourless) measuring spoon.
Kartonska kutija sadrži jednu HDPE (bijelu) posudu s LDPE poklopcem sa zaštitnom trakom sadrži 180 grama ili 504 grama peroralnog praška i jednu polistirensku (bezbojnu) mjernu žlicu.
Cardboard box containing one polyethylene bottle of 100 ml or 250 ml with a polyethylene tip adapter and a tamper proof child resistant closure and a measuring syringe.
Kartonska kutija sadrži jednu polietilensku bočicu od 100 ml ili 250 ml s polietilenskim adapterom vrha i zatvaračem za zaštitu od djece te mjerna štrcaljka.
Cardboard box containing one polyethylene bottle of 100 ml or 250 ml with a polyethylene tip adapter, a tamper proof child resistant closure and a measuring syringe.
Kartonska kutija sadrži jednu polietilensku bocu od 100 ml ili 250 ml s polietilenskim adapterom vrha, zatvaračem za zaštitu od djece te mjernom štrcaljkom.
Cardboard box containing polyethylene bottles with a chlorobutyl elastomer closure and sealed with an aluminium cap.
Kartonska kutija sadrži polietilensku bočicu sa klorbutilnim elastomernim čepom i aluminijskom kapicom.
Cardboard box containing20 pentalaminate sachets (inner coating LDPE) of 3 g (containing 100 mg prednisolone), or 10 sachets of 9 g (200 mg) or 18 g (300 mg) of oral powder.
Kartonska kutija sadrži 20 pentalaminatna vrećica (unutarnji sloj od LDPE) od 3 g (sadrži 100 mg prednizolona), ili 10 vrećica od 9 g (sadrži 300 mg prednizolona) ili 18 g (sadrži 600 mg prednizolona) peroralnog praška.
CARDBOARD BOX FOR 1-DOSE VIAL
KARTONSKA KUTIJA ZA 1-DOZNU BOČICU
CARDBOARD BOX FOR 10-DOSE VIAL
KARTONSKA KUTIJA ZA 10-DOZNU BOČICU
CARDBOARD BOX FOR 10-DOSE VIAL
KARTONSKA KUTIJA ZA BOČICU S 10 DOZA
Cardboard box for 20ml, 50 ml, 100 ml
Kartonska kutija za 20 ml, 50 ml, 100 ml
CARDBOARD BOX FOR SYRINGE
KARTONSKA KUTIJA ZA ŠTRCALJKU
Cardboard box of 1 bottle of 10 doses (20 ml), 50 doses (100 ml) or 125 doses (250 ml).
Kartonska kutija sa jednom bočicom od 10 doza (20 ml), 50 doza (100 ml) ili 125 doza (250 ml).
Cardboard box of 1 bottle of 30 tablets
Kartonska kutija s 1 bočicom s 30 tableta
Cardboard box of 1 bottle of 30 tablets Cardboard box of 1 bottle of 90 tablets
Kartonska kutija s jednom bocom od 30 tableta Kartonska kutija s jednom bocom od 90 tableta
Cardboard box of 1 vial of 2,500 doses.
Kartonska kutija s 1 bočicom s 2.500 doza.
Cardboard box of 1, 3, 4, 6, 12, 24 and 72 spot-on applicators
Kartonska kutija s 1, 3, 4, 6, 12, 24 ili 72 aplikatora za nakapavanje
Cardboard box of 1, 3, 4, 6, 12, 24 or 48 spot-on applicators of 0.8 ml, 1.6 ml, 3.6 ml, 4.7 ml or 8.0 ml. (Only one size per box.)
Kartonska kutija sadrži 1, 3, 4, 6, 12, 24 ili 48 aplikatora za nakapavanje s 0,8 ml, 1,6 ml, 3,6 ml, 4,7 ml ili 8,0 ml. (Samo jedna veličina po kutiji.)
Cardboard box of 1, 3, 4, 6, 12, 24 or 72 spot-on applicator(s).
Kartonska kutija s 1, 3, 4, 6, 12, 24 ili 72 aplikatora za nakapavanje.
Cardboard box of 1, 4 or 6 spot-on applicators, consisting of 0.51, 0.77, 1.03, 1.54, 3.08 and 4.62 ml pipettes.
Kartonska kutija od 1, 4 ili 6 spot on aplikatora, koji se sastoje od pipeta s 0,51, 0,77, 1,03, 1,54, 3,08 i 4,62 ml.
Cardboard box of 1, 4 or 6 spot-on pipettes consisting of 0.5 ml, 1 ml 2 ml, 4 ml, and 6 ml pipettes.
Kartonska kutija s 1, 4 ili 6 pipeta, s pipetama od 0,5 ml, 1 ml, 2 ml, 4 ml i 6 ml.
Cardboard box of 10 ml vial
Kartonska kutija za bočicu od 10 ml
Cardboard box of 10 ml vial Cardboard box of 32 ml vial Cardboard box of 100 ml vial
Kartonska kutija za bočicu od 10 ml Kartonska kutija za bočicu od 32 ml Kartonska kutija za bočicu od 100 ml
Cardboard box of 15 ml vial Cardboard box of 5 ml vial
Kartonska kutija za bočicu od 15 ml Kartonska kutija za bočicu od 5 ml
Cardboard box of 50 ml vial Cardboard box of 100 ml vial Cardboard box of 250 ml vial
Kartonska kutija za bočicu od 50 ml Kartonska kutija za bočicu od 100 ml Kartonska kutija za bočicu od 250 ml
Cardboard box of 6 vials of 1 dose of lyophilisate and 6 vials of 1 ml of solvent.
Kartonska kutija od 6 bočica s po 1 dozom liofilizata i 6 bočica od 1 ml otapala.
Cardboard box of 6 vials of lyophilisate and 6 vials of solvent
Kartonska kutija sa 6 bočica liofilizata i 6 bočica otapala